<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37101208</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Risk of new-onset glaucoma in patients with systemic lupus erythematosus: A nationwide, population-based cohort study.</ArticleTitle><Pagination><StartPage>1076</StartPage><EndPage>1082</EndPage><MedlinePgn>1076-1082</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14698</ELocationID><Abstract><AbstractText>To explore the relationship of systemic lupus erythematosus (SLE) and subsequent glaucoma incidence. Patients with SLE were defined as those newly diagnosed by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 710.0 in at least 3 outpatient visits or 1 hospitalization during 2000-2012 by using the National Health Insurance Research Database. We selected a non-SLE comparison cohort at a 1:1 ratio by propensity score matching on age, gender, index date, comorbidities and medications. We identified outcome as the incident glaucoma in patients with SLE. Multivariate Cox regression analysis was used to calculate the adjusted hazard ratio (aHR) in 2 groups. Kaplan- Meier analysis was performed to estimate the cumulative incidence rate between both groups. There were 1743 patients who were included in the SLE group and non-SLE group. The aHR of glaucoma was 1.56 (95% CI&#x2009;=&#x2009;1.03-2.36) in the SLE group, compared to non-SLE controls. Subgroup analysis showed that SLE patients present greater risk of glaucoma, especially in males (aHR&#x2009;=&#x2009;3.76; 95% CI, 1.5-9.42), and the P for interaction between gender and risk of glaucoma was 0.026. This cohort study showed that patients with SLE have 1.56-fold risk of glaucoma development. Gender acted as an effect modifier between SLE and the risk of new-onset glaucoma.</AbstractText><CopyrightInformation>&#xa9; 2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yi-Chiao</ForeName><Initials>YC</Initials><Identifier Source="ORCID">0009-0006-4125-2142</Identifier><AffiliationInfo><Affiliation>Institute of Medicine, Chung Shan Medical University, Taichung, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Optometry, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Allergy, Immunology and Rheumatology, Cheng Ching Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perng</LastName><ForeName>Wuu-Tsun</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Department of Recreational Sport &amp; Health Promotion, National Pingtung University of Science and Technology, Pingtung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Yao-Min</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0001-6920-8799</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, MeiHo University, Pingtung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tajen University, Pingtung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu-Hsun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>James Cheng-Chung</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-1235-0679</Identifier><AffiliationInfo><Affiliation>Institute of Medicine, Chung Shan Medical University, Taichung, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005901" MajorTopicYN="Y">Glaucoma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37101208</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14698</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Miele A, Govetto A, Fumagalli C, et al. Ocular hypertension and glaucoma. Following vitrectomy: a systematic review. Retina. 2018;38(5):883-890.</Citation></Reference><Reference><Citation>Weinreb RN, Leung CKS, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016;2:16068.</Citation></Reference><Reference><Citation>Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.</Citation></Reference><Reference><Citation>Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129-140.</Citation></Reference><Reference><Citation>Reinehr S, Buschhorn V, Mueller-Buehl AM, et al. Occurrence of retinal ganglion cell loss via autophagy and apoptotic pathways in an autoimmune glaucoma model. Curr Eye Res. 2020;45:1124-1135.</Citation></Reference><Reference><Citation>Wey S, Amanullah S, Spaeth GL, et al. Is primary open-angle glaucoma an ocular manifestation of systemic disease? Graefes Arch Clin Exp Ophthalmol. 2019;257(4):665-673.</Citation></Reference><Reference><Citation>Shigesi N, Kvaskoff M, Kirtley S, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):486-503.</Citation></Reference><Reference><Citation>Resch MD, Marsovszky L, N&#xe9;meth J, et al. Dry eye and corneal langerhans cells in systemic lupus erythematosus. J Ophthalmol. 2015;2015:543835.</Citation></Reference><Reference><Citation>Omdal R, L&#xf8;seth S, Torbergsen T, Koldingsnes W, Husby G, Mellgren SI. Peripheral neuropathy in systemic lupus erythematosus-a longitudinal study. Acta Neurol Scand. 2001;103(6):386-391.</Citation></Reference><Reference><Citation>Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus. 2010;19(10):1250-1255.</Citation></Reference><Reference><Citation>Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun. 2020;110:102356.</Citation></Reference><Reference><Citation>Conigliaro P, Cesareo M, Chimenti MS, et al. Take a look at the eyes in systemic lupus erythematosus: a novel point of view. Autoimmun Rev. 2019;18(3):247-254.</Citation></Reference><Reference><Citation>Dias-Santos A, Tavares Ferreira J, Pinheiro S, et al. Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center. Lupus. 2020;29(3):283-289.</Citation></Reference><Reference><Citation>Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898.</Citation></Reference><Reference><Citation>Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071-1073.</Citation></Reference><Reference><Citation>Zhu FX, Huang JY, Ye Z, Wen QQ, Wei JCC. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis. 2020;79(6):793-799.</Citation></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism/American College of Rheumatology Classification Criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.</Citation></Reference><Reference><Citation>Yang DH, Leong PY, Sia SK, Wang YH, Wei JCC. Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus. J Clin Med. 2019;8(6):796.</Citation></Reference><Reference><Citation>Lee DH, Lee SC, Kim M. Acute macular neuroretinopathy associated with systemic lupus erythematosus. Lupus. 2016;25(4):431-435.</Citation></Reference><Reference><Citation>Liu GY, Utset TO, Bernard JT. Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLE. Lupus. 2015;24(11):1169-1176.</Citation></Reference><Reference><Citation>Chaiwiang N, Poyomtip T. Microbial dysbiosis and microbiota-gut-retina axis: the lesson from brain neurodegenerative diseases to primary open-angle glaucoma pathogenesis of autoimmunity. Acta Microbiol Immunol Hung. 2019;66(4):541-558.</Citation></Reference><Reference><Citation>Ayaki M, Shiba D, Negishi K, Tsubota K. Depressed visual field and mood are associated with sleep disorder in glaucoma patients. Sci Rep. 2016;6:25699.</Citation></Reference><Reference><Citation>Bussel II, Aref AA. Dietary factors and the risk of glaucoma: a review. Ther Adv Chronic Dis. 2014;5(4):188-194.</Citation></Reference><Reference><Citation>Ci W, Zhao J, Qi W, et al. Characteristics and risk factors. Of severe coronary. Artery. Disease in systemic lupus erythematosus: a multicenter, Chinese rheumatism date center database study. Int J Rheum Dis. 2022;25(10):1186-1195.</Citation></Reference><Reference><Citation>Qin Q, Zhao L, Ren A, et al. Systemic lupus erythematosus is causally associated with hypothyroidism, but not hyperthyroidism: a mendelian randomization study. Front Immunol. 2023;14:1125415.</Citation></Reference><Reference><Citation>Chen Y, Fu L, Sijia P, et al. Systemic lupus erythematosus increases. Risk of incident. Atrial fibrillation: a systematic review and meta-analysis. Int J Rheum Dis. 2022;25(10):1097-1106.</Citation></Reference><Reference><Citation>Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275-281.</Citation></Reference><Reference><Citation>Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163-167.</Citation></Reference><Reference><Citation>Aranow C, Del Guidice J, Barland P, et al. Systemic lupus erythematosus disease severity in men and women: a case-control study. J Rheumatol. 2002;29(8):1674-1677.</Citation></Reference><Reference><Citation>Tan TC, Fang H, Magder LS, et al. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012;39(4):759-769.</Citation></Reference><Reference><Citation>Lin TM, Chang YS, Hou TY, et al. Risk of incident autoimmune diseases in patients with thymectomy. Ann Clin Transl Neurol. 2020;7(7):1072-1082.</Citation></Reference><Reference><Citation>Joachim SC, Grus FH, Kraft D, et al. Complex antibody profile changes in an experimental autoimmune glaucoma animal model. Invest Ophthalmol Vis Sci. 2009;50(10):4734-4742.</Citation></Reference><Reference><Citation>Zhang W, Dong X, Wang T, Kong Y. Exosomes derived from platelet-rich plasma mediate hyperglycemia-induced retinal endothelial injury via targeting the TLR4 signaling pathway. Exp Eye Res. 2019;189:107813.</Citation></Reference><Reference><Citation>Li N, Zhao L, Wei Y, Ea VL, Nian H, Wei R. Recent advances of exosomes in immune-mediated eye diseases. Stem Cell Res Ther. 2019;10(1):278.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>